Skip to content

Allphase Pharma Consulting, LLC

A Professional Service Provider for the Pharma Industry

Allphase Pharma Consulting, LLC
Menu

Primary menu

  • CONTACT
  • BLOGS
    • The Viewpoint
    • The News
    • Recent Literature
    • Did you know…?
    • QIDP Antibiotics
  • LEGAL
  • WELCOME

Secondary menu

  • The News
  • The Viewpoint
  • Did you know…?
  • Recent Literature
  • QIDP Antibiotics

Tag Archives: BAL

Meropenem Dosing for VAP: High + Prolonged Beats Conventional Dosing

Posted on January 6, 2015 by Harald — No Comments ↓

Sometimes an article pops up addressing a question we have been mulling over for quite some time.  It so happened with a recent publication which shed new light on penem dosing for ICU patients[1]. Conducted at a single Belgian centre (sic!), a standard dose of meropenem (1 g IV q8h Continue reading Meropenem Dosing for VAP: High + Prolonged Beats Conventional Dosing→

Share this:

  • Click to share on LinkedIn (Opens in new window) LinkedIn
  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X
  • Click to print (Opens in new window) Print
  • Click to email a link to a friend (Opens in new window) Email
  • Click to share on WhatsApp (Opens in new window) WhatsApp

Like this:

Like Loading...
Posted in Recent Literature, The Viewpoint | Tagged antibiotic blog, antibiotic dosing, attainment rate, BAL, CAP, ceftobiprole, cIAI, cSSSI, Doribax, doripenem, ELF levels, EMA, FDA, FDA Guidance, HAP, HAP/VAP, ICU, imipenem, labeling, meropenem, Merrem, nosocomial pneumonia, penem, PK/PD, Primaxin, seizure, T>MIC, tigecyc, tigecycline | Leave a reply

Go back

Your message has been sent

Rating(required)
Warning

Footer Menu

Footer menu

  • CONTACT
  • BLOGS
  • LEGAL
  • WELCOME
  • Email
Copyright © 2026 Allphase Pharma Consulting, LLC. All Rights Reserved.
Theme: Catch Box by Catch Themes
Scroll Up
%d